19 results on '"Mathiassen, Ole N."'
Search Results
2. Coronary CT Angiographic and Flow Reserve-Guided Management of Patients With Stable Ischemic Heart Disease
- Author
-
Nørgaard, Bjarne L., Terkelsen, Christian J., Mathiassen, Ole N., Grove, Erik L., Bøtker, Hans Erik, Parner, Erik, Leipsic, Jonathon, Steffensen, Flemming H., Riis, Anders H., Pedersen, Kamilla, Christiansen, Evald H., Mæng, Michael, Krusell, Lars R., Kristensen, Steen D., Eftekhari, Ashkan, Jakobsen, Lars, and Jensen, Jesper M.
- Published
- 2018
- Full Text
- View/download PDF
3. Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial
- Author
-
Engholm, Morten, Bertelsen, Jannik B., Mathiassen, Ole N., Bøtker, Hans E., Vase, Henrik, Peters, Christian D., Bech, Jesper N., Buus, Niels H., Schroeder, Anne P., Rickers, Hans, Hansen, Klavs W., Poulsen, Per L., Kaltoft, Anne, and Christensen, Kent L.
- Published
- 2018
- Full Text
- View/download PDF
4. Influence of intensive lipid‐lowering on CT derived fractional flow reserve in patients with stable chest pain: Rationale and design of the FLOWPROMOTE study.
- Author
-
Mortensen, Martin B., Sand, Niels‐Peter, Busk, Martin, Jensen, Jesper M., Grove, Erik L., Dey, Damini, Iraqi, Nadia, Updegrove, Adam, Fonte, Tim, Mathiassen, Ole N., Hosbond, Susanne, Bøtker, Hans E., Leipsic, Jonathon, Narula, Jagat, and Nørgaard, Bjarne L.
- Subjects
CHEST pain ,CORONARY artery stenosis ,CORONARY artery disease ,CORONARY angiography ,STATINS (Cardiovascular agents) - Abstract
Introduction: Coronary CT angiography (CTA) derived fractional flow reserve (FFRCT) shows high diagnostic performance when compared to invasively measured FFR. Presence and extent of low attenuation plaque density have been shown to be associated with abnormal physiology by measured FFR. Moreover, it is well established that statin therapy reduces the rate of plaque progression and results in morphology alterations underlying atherosclerosis. However, the interplay between lipid lowering treatment, plaque regression, and the coronary physiology has not previously been investigated. Aim: To test whether lipid lowering therapy is associated with significant improvement in FFRCT, and whether there is a dose–response relationship between lipid lowering intensity, plaque regression, and coronary flow recovery. Methods: Investigator driven, prospective, multicenter, randomized study of patients with stable angina, coronary stenosis ≥50% determined by clinically indicated first‐line CTA, and FFRCT ≤ 0.80 in whom coronary revascularization was deferred. Patients are randomized to standard (atorvastatin 40 mg daily) or intensive (rosuvastatin 40 mg + ezetimibe 10 mg daily) lipid lowering therapy for 18 months. Coronary CTA scans with blinded coronary plaque and FFRCT analyses will be repeated after 9 and 18 months. The primary endpoint is the 18‐month difference in FFRCT using (1) the FFRCT value 2 cm distal to stenosis and (2) the lowest distal value in the vessel of interest. A total of 104 patients will be included in the study. Conclusion: The results of this study will provide novel insights into the interplay between lipid lowering, and the pathophysiology in coronary artery disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Clinical outcomes following real-world computed tomography angiography-derived fractional flow reserve testing in chronic coronary syndrome patients with calcification.
- Author
-
Nørgaard, Bjarne L, Mortensen, Martin B, Parner, Erik, Leipsic, Jonathon, Steffensen, Flemming H, Grove, Erik Lerkevang, Mathiassen, Ole N, Sand, Niels Peter, Pedersen, Kamilla, Riedl, Katharina A, Engholm, Morten, Bøtker, Hans Erik, and Jensen, Jesper M
- Subjects
CORONARY arterial radiography ,CALCIUM metabolism ,BLOOD vessels ,SCIENTIFIC observation ,CORONARY artery stenosis ,ANGINA pectoris ,MYOCARDIAL infarction ,CORONARY circulation ,TREATMENT effectiveness ,CORONARY artery disease ,HEART function tests ,CALCINOSIS ,HOSPITAL care ,MYOCARDIAL revascularization ,DESCRIPTIVE statistics ,COMPUTED tomography ,CORONARY arteries ,PATIENT safety ,DISEASE risk factors - Abstract
Aims This study sought to investigate outcomes following a normal CT-derived fractional flow reserve (FFR
CT ) result in patients with moderate stenosis and coronary artery calcification, and to describe the relationship between the extent of calcification, stenosis, andFFR CT. Methods and results Data from 975 consecutive patients suspected of chronic coronary syndrome with stenosis (30–70%) determined by computed CT angiography and FFRCT to guide downstream management decisions were reviewed. Median (range) follow-up time was 2.2 (0.5–4.2) years. Coronary artery calcium (CAC) scores were ≥400 in 25%, stenosis ≥50% in 83%, and FFRCT >0.80 in 51% of the patients. There was a lower incidence of the composite endpoint (death, myocardial infarction, hospitalization for unstable angina, and unplanned coronary revascularization) at 4.2 years in patients with any CAC and FFRCT > 0.80 vs. FFRCT ≤ 0.80 (3.9% and 8.7%, P = 0.04), however, in patients with CAC scores ≥400 the risk difference between groups did not reach statistical significance, 4.2% vs. 9.7% (P = 0.24). A negative relationship between CAC scores and FFRCT irrespective of stenosis severity was demonstrated. Conclusion FFRCT shows promise in identifying patients with stenosis and calcification who can be managed without further downstream testing. Moreover, an inverse relationship between CAC levels and FFRCT was demonstrated. Studies are needed to further assess the clinical utility of FFRCT in patients with extensive coronary calcification. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. Transcatheter Aortic Heart Valve Thrombosis:Incidence, Predisposing Factors, and Clinical Implications
- Author
-
Hansson, Nicolaj C, Grove, Erik L, Andersen, Henning R, Leipsic, Jonathon, Mathiassen, Ole N, Jensen, Jesper M, Jensen, Kaare T, Blanke, Philipp, Leetmaa, Tina, Tang, Mariann, Krusell, Lars R, Klaaborg, Kaj E, Christiansen, Evald H, Terp, Kim, Terkelsen, Christian J, Poulsen, Steen H, Webb, John, Bøtker, Hans Erik, and Nørgaard, Bjarne L
- Abstract
BACKGROUND: There is increasing focus on transcatheter heart valve (THV) thrombosis. However, there are limited data on incidence, clinical implications and predisposing factors of THV thrombosis following transcatheter aortic valve replacement (TAVR).OBJECTIVES: We assessed the incidence, potential predictors, and clinical implications of THV thrombosis determined by contrast-enhanced multidetector computed tomography (MDCT) after TAVR.METHODS: Among 460 consecutive patients undergoing TAVR with the Edwards Sapien XT or Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) valves, 405 (88%) underwent MDCT in addition to transthoracic and transesophageal echocardiography 1-3 months post-TAVR. MDCT scans were evaluated for hypo-attenuated leaflet thickening indicating THV thrombosis.RESULTS: MDCT verified THV thrombosis in 28 of 405 (7%) patients. A total of 23 patients had subclinical THV thrombosis, while 5 (18%) patients experienced clinically overt obstructive THV thrombosis. THV thrombosis risk did not differ between the Edwards Sapien XT and the Sapien 3 valves, 8% (14/173) vs. 6% (14/232) (p=0.42). The risk of THV thrombosis in patients not receiving warfarin was higher compared to patients receiving warfarin, 10.7% vs. 1.8%; RR, 95%CI: 6.09, 1.86-19.84. A larger THV was associated with an increased THV thrombosis risk (p=0.03). In multivariable analysis, 29 mm THV (RR, 95%CI: 2.89, 1.44-5.80) and no post-TAVR warfarin treatment (RR, 95%CI: 5.46, 1.68-17.7), independently predicted THV thrombosis. Treatment with warfarin effectively reverted THV thrombosis and normalized THV function in 85% of patients as documented by follow-up transesophageal echocardiography and MDCT.CONCLUSIONS: The incidence of THV thrombosis in this large study was 7%. Larger THV size may predispose to THV thrombosis, whereas treatment with warfarin appears to have a protective effect. Although often subclinical, THV thrombosis may have important clinical implications.
- Published
- 2016
7. Effects of Renal Denervation on Insulin Sensitivity and Inflammatory Markers in Nondiabetic Patients with Treatment-Resistant Hypertension.
- Author
-
Kampmann, Ulla, Mathiassen, Ole N., Christensen, Kent L., Buus, Niels H., Bjerre, Mette, Vase, Henrik, Møller, Niels, Kaltoft, Anne, and Poulsen, Per L.
- Subjects
- *
INSULIN resistance , *HYPERTENSION risk factors , *GLUCOSE metabolism , *BLOOD pressure , *CATHETER ablation , *RENAL artery , *PATIENTS , *SURGERY - Abstract
Increased sympathetic activity is important in the pathogenesis of hypertension and insulin resistance. Afferent signaling from the kidneys elevates the central sympathetic drive. We investigated the effect of catheter-based renal sympathetic denervation (RDN) on glucose metabolism, inflammatory markers, and blood pressure in nondiabetic patients with treatment-resistant hypertension. Eight subjects were included in an open-labelled study. Each patient was studied before and 6 months after RDN. Endogenous glucose production was assessed by a 3-3H glucose tracer, insulin sensitivity was examined by hyperinsulinemic euglycemic clamp, hormones and inflammatory markers were analyzed, and blood pressure was measured by office blood pressure readings and 24-hour ambulatory blood pressure monitoring. Insulin sensitivity (M-value) increased nonsignificantly from 2.68 ± 0.28 to 3.07 ± 0.41 (p=0.12). A significant inverse correlation between the increase in M-value and BMI 6 months after RDN (p=0.03) was found, suggesting beneficial effects on leaner subjects. Blood pressure decreased significantly, but there were no changes in hormones, inflammatory markers, or endogenous glucose production. Our results indicate that RDN may improve insulin sensitivity in some patients with treatment-resistant hypertension, albeit confirmation of these indications of beneficial effects on leaner subjects awaits the outcome of larger randomized controlled studies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Myocardial Perfusion Imaging Versus Computed Tomography Angiography–Derived Fractional Flow Reserve Testing in Stable Patients With Intermediate‐Range Coronary Lesions: Influence on Downstream Diagnostic Workflows and Invasive Angiography Findings.
- Author
-
Nørgaard, Bjarne L., Gormsen, Lars C., Bøtker, Hans Erik, Parner, Erik, Nielsen, Lene H., Mathiassen, Ole N., Grove, Erik L., Øvrehus, Kristian A., Gaur, Sara, Leipsic, Jonathon, Pedersen, Kamilla, Terkelsen, Christian J., Christiansen, Evald H., Kaltoft, Anne, Mæng, Michael, Kristensen, Steen D., Krusell, Lars R., Lassen, Jens F., and Jensen, Jesper M.
- Published
- 2017
- Full Text
- View/download PDF
9. Clinical Use of Coronary CTA–Derived FFR for Decision-Making in Stable CAD.
- Author
-
Nørgaard, Bjarne L., Hjort, Jakob, Gaur, Sara, Hansson, Nicolaj, Bøtker, Hans Erik, Leipsic, Jonathon, Mathiassen, Ole N., Grove, Erik L., Pedersen, Kamilla, Christiansen, Evald H., Kaltoft, Anne, Gormsen, Lars C., Mæng, Michael, Terkelsen, Christian J., Kristensen, Steen D., Krusell, Lars R., and Jensen, Jesper M.
- Abstract
Objectives The goal of this study was to assess the real-world clinical utility of fractional flow reserve (FFR) derived from coronary computed tomography angiography (FFR CT ) for decision-making in patients with stable coronary artery disease (CAD). Background FFR CT has shown promising results in identifying lesion-specific ischemia. The real-world feasibility and influence on the diagnostic work-up of FFR CT testing in patients suspected of having CAD are unknown. Methods We reviewed the complete diagnostic work-up of nonemergent patients referred for coronary computed tomography angiography over a 12-month period at Aarhus University Hospital, Denmark, including all patients with new-onset chest pain with no known CAD and with intermediate-range coronary lesions (lumen reduction, 30% to 70%) referred for FFR CT . The study evaluated the consequences on downstream diagnostic testing, the agreement between FFR CT and invasively measured FFR or instantaneous wave-free ratio (iFR), and the short-term clinical outcome after FFR CT testing. Results Among 1,248 patients referred for computed tomography angiography, 189 patients (mean age 59 years; 59% male) were referred for FFR CT , with a conclusive FFR CT result obtained in 185 (98%). FFR CT was ≤0.80 in 31% of patients and 10% of vessels. After FFR CT testing, invasive angiography was performed in 29%, with FFR measured in 19% and iFR in 1% of patients (with a tendency toward declining FFR-iFR guidance during the study period). FFR CT ≤0.80 correctly classified 73% (27 of 37) of patients and 70% (37 of 53) of vessels using FFR ≤0.80 or iFR ≤0.90 as the reference standard. In patients with FFR CT >0.80 being deferred from invasive coronary angiography, no adverse cardiac events occurred during a median follow-up period of 12 (range 6 to 18 months) months. Conclusions FFR CT testing is feasible in real-world symptomatic patients with intermediate-range stenosis determined by coronary computed tomography angiography. Implementation of FFR CT for clinical decision-making may influence the downstream diagnostic workflow of patients. Patients with an FFR CT value >0.80 being deferred from invasive coronary angiography have a favorable short-term prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Renal denervation in treatment resistant hypertension: effects on coronary flow reserve and forearm dilation capacity. A randomized, double-blinded, SHAM-controlled clinical trial
- Author
-
Engholm, Morten, Bertelsen, Jannik B., Mathiassen, Ole N., Vase, Henrik, Bech, Jesper N., Schroeder, Anne P., Lederballe, Ole, Rickers, Hans, Peters, Christian D., Kampmannf, Ulla, Poulsen, Per L., Langfeldt, Sten, Andersen, Gratien, Hansen, Klavs W., Pedersen, Erling B., Lassen, Jens F., Boetker, Hans E., Buus, Niels H., Kaltoft, Anne, and Christensen, Kent L.
- Published
- 2016
- Full Text
- View/download PDF
11. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial.
- Author
-
Mathiassen, Ole N., Vase, Henrik, Bech, Jesper N., Christensen, Kent L., Buus, Niels H., Schroeder, Anne P., Lederballe, Ole, Rickers, Hans, Kampmann, Ulla, Poulsen, Per L., Hansen, Klavs W., Bøtker, Hans E., Peters, Christian D., Engholm, Morten, Bertelsen, Jannik B., Lassen, Jens F., Langfeldt, Sten, Andersen, Gratien, Pedersen, Erling B., and Kaltoft, Anne
- Published
- 2016
- Full Text
- View/download PDF
12. Small artery structure during antihypertensive therapy is an independent predictor of cardiovascular events in essential hypertension.
- Author
-
Buus, Niels H, Mathiassen, Ole N, Fenger-Grøn, Morten, Præstholm, Michael N, Sihm, Inger, Thybo, Niels K, Schroeder, Anne P, Thygesen, Kristian, Aalkjær, Christian, Pedersen, Ole L, Mulvany, Michael J, and Christensen, Kent L
- Published
- 2013
- Full Text
- View/download PDF
13. TCT-89 Renal Sympathetic Denervation in Treatment Resistant Essential Hypertension. A Sham-Controlled, Double-blinded Randomized Trial (ReSET trial).
- Author
-
Mathiassen, Ole N., Bech, Jesper N., Buus, Niels Henrik, Christensen, Kent L., Vase, Henrik, Bertelsen, Jannik B., Hans, Rickers, Kampmann, Ulla, Pedersen, Morten E., Pedersen, Ole L., Peters, Christian D., Poulsen, Per L., Lassen, Jens F., Würgler, Klavs, Boetker, Hans Erik, Schroeder, Pauline, Pedersen, Erling B., and Kaltoft, Anne
- Subjects
- *
DENERVATION , *ENDOSCOPIC surgery , *KIDNEY disease treatments , *HYPERTENSION , *THERAPEUTICS , *RANDOMIZED controlled trials - Published
- 2015
- Full Text
- View/download PDF
14. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
- Author
-
De Backer, Ole, Dangas, George D., Jilaihawi, Hasan, Leipsic, Jonathon A., Terkelsen, Christian J., Makkar, Raj, Kini, Annapoorna S., Veien, Karsten T., Abdel-Wahab, Mohamed, Kim, Won-Keun, Balan, Prakash, Van Mieghem, Nicolas, Mathiassen, Ole N., Jeger, Raban V., Arnold, Martin, Mehran, Roxana, Guimarães, Ana H. C., Nørgaard, Bjarne L., Kofoed, Klaus F., and Blanke, Philipp
- Subjects
- *
ANTICOAGULANTS , *AORTIC valve , *ASPIRIN , *ATRIAL fibrillation , *COMBINATION drug therapy , *CLINICAL trials , *COMPARATIVE studies , *COMPUTED tomography , *PROSTHETIC heart valves , *HEMORRHAGE , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *THROMBOEMBOLISM , *EVALUATION research , *PLATELET aggregation inhibitors , *PHARMACODYNAMICS ,CARDIOVASCULAR disease related mortality - Abstract
Background: Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed tomography (CT). Whether anticoagulation can reduce these phenomena after transcatheter aortic-valve replacement (TAVR) is not known.Methods: In a substudy of a large randomized trial, we randomly assigned patients who had undergone successful TAVR and who did not have an indication for long-term anticoagulation to a rivaroxaban-based antithrombotic strategy (rivaroxaban [10 mg] plus aspirin [75 to 100 mg] once daily) or an antiplatelet-based strategy (clopidogrel [75 mg] plus aspirin [75 to 100 mg] once daily). Patients underwent evaluation by four-dimensional CT at a mean (±SD) of 90±15 days after randomization. The primary end point was the percentage of patients with at least one prosthetic valve leaflet with grade 3 or higher motion reduction (i.e., involving >50% of the leaflet). Leaflet thickening was also assessed.Results: A total of 231 patients were enrolled. At least one prosthetic valve leaflet with grade 3 or higher motion reduction was found in 2 of 97 patients (2.1%) who had scans that could be evaluated in the rivaroxaban group, as compared with 11 of 101 (10.9%) in the antiplatelet group (difference, -8.8 percentage points; 95% confidence interval [CI], -16.5 to -1.9; P = 0.01). Thickening of at least one leaflet was observed in 12 of 97 patients (12.4%) in the rivaroxaban group and in 33 of 102 (32.4%) in the antiplatelet group (difference, -20.0 percentage points; 95% CI, -30.9 to -8.5). In the main trial, the risk of death or thromboembolic events and the risk of life-threatening, disabling, or major bleeding were higher with rivaroxaban (hazard ratios of 1.35 and 1.50, respectively).Conclusions: In a substudy of a trial involving patients without an indication for long-term anticoagulation who had undergone successful TAVR, a rivaroxaban-based antithrombotic strategy was more effective than an antiplatelet-based strategy in preventing subclinical leaflet-motion abnormalities. However, in the main trial, the rivaroxaban-based strategy was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than the antiplatelet-based strategy. (Funded by Bayer; GALILEO-4D ClinicalTrials.gov number, NCT02833948.). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
15. Transcatheter Aortic Valve Thrombosis: Incidence, Predisposing Factors, and Clinical Implications.
- Author
-
Hansson, Nicolaj C., Grove, Erik L., Andersen, Henning R., Leipsic, Jonathon, Mathiassen, Ole N., Jensen, Jesper M., Jensen, Kaare T., Blanke, Philipp, Leetmaa, Tina, Tang, Mariann, Krusell, Lars R., Klaaborg, Kaj E., Christiansen, Evald H., Terp, Kim, Terkelsen, Christian J., Poulsen, Steen H., Webb, John, Bøtker, Hans Erik, and Nørgaard, Bjarne L.
- Subjects
- *
AORTIC valve diseases , *THROMBOSIS , *DISEASE incidence , *DISEASE susceptibility , *TRANSESOPHAGEAL echocardiography , *THROMBOSIS diagnosis , *AORTIC valve , *AORTIC stenosis , *PROSTHETIC heart valves , *LONGITUDINAL method , *PROGNOSIS , *RETROSPECTIVE studies , *SURGICAL complications , *MULTIDETECTOR computed tomography , *DIAGNOSIS ,AORTIC valve surgery - Abstract
Background: There are limited data on the incidence, clinical implications, and predisposing factors of transcatheter heart valve (THV) thrombosis following transcatheter aortic valve replacement (TAVR).Objectives: The authors assessed the incidence, potential predictors, and clinical implications of THV thrombosis as determined by contrast-enhanced multidetector computed tomography (MDCT) after TAVR.Methods: Among 460 consecutive patients who underwent TAVR with the Edwards Sapien XT or Sapien 3 (Edwards Lifesciences, Irvine, California) THV, 405 (88%) underwent MDCT in addition to transthoracic and transesophageal echocardiography 1 to 3 months post-TAVR. MDCT scans were evaluated for hypoattenuated leaflet thickening that indicated THV thrombosis.Results: MDCT verified THV thrombosis in 28 of 405 (7%) patients. A total of 23 patients had subclinical THV thrombosis, whereas 5 (18%) patients experienced clinically overt obstructive THV thrombosis. THV thrombosis risk did not differ among different generations of THVs (8% vs. 6%; p = 0.42). The risk of THV thrombosis in patients who did not receive warfarin was higher compared with patients who received warfarin (10.7% vs. 1.8%; risk ratio [RR]: 6.09; 95% confidence interval [CI]: 1.86 to 19.84). A larger THV was associated with an increased risk of THV thrombosis (p = 0.03). In multivariable analysis, a 29-mm THV (RR: 2.89; 95% CI: 1.44 to 5.80) and no post-TAVR warfarin treatment (RR: 5.46; 95% CI: 1.68 to 17.7) independently predicted THV thrombosis. Treatment with warfarin effectively reverted THV thrombosis and normalized THV function in 85% of patients as documented by follow-up transesophageal echocardiography and MDCT.Conclusions: Incidence of THV thrombosis in this large study was 7%. A larger THV size may predispose to THV thrombosis, whereas treatment with warfarin appears to have a protective effect. Although often subclinical, THV thrombosis may have important clinical implications. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
16. Clinical outcomes following real-world computed tomography angiography-derived fractional flow reserve testing in chronic coronary syndrome patients with calcification.
- Author
-
Nørgaard BL, Mortensen MB, Parner E, Leipsic J, Steffensen FH, Grove EL, Mathiassen ON, Sand NP, Pedersen K, Riedl KA, Engholm M, Bøtker HE, and Jensen JM
- Subjects
- Computed Tomography Angiography, Coronary Angiography, Coronary Vessels, Humans, Predictive Value of Tests, Severity of Illness Index, Tomography, X-Ray Computed, Coronary Artery Disease diagnostic imaging, Coronary Stenosis diagnostic imaging, Fractional Flow Reserve, Myocardial
- Abstract
Aims: This study sought to investigate outcomes following a normal CT-derived fractional flow reserve (FFRCT) result in patients with moderate stenosis and coronary artery calcification, and to describe the relationship between the extent of calcification, stenosis, and FFRCT., Methods and Results: Data from 975 consecutive patients suspected of chronic coronary syndrome with stenosis (30-70%) determined by computed CT angiography and FFRCT to guide downstream management decisions were reviewed. Median (range) follow-up time was 2.2 (0.5-4.2) years. Coronary artery calcium (CAC) scores were ≥400 in 25%, stenosis ≥50% in 83%, and FFRCT >0.80 in 51% of the patients. There was a lower incidence of the composite endpoint (death, myocardial infarction, hospitalization for unstable angina, and unplanned coronary revascularization) at 4.2 years in patients with any CAC and FFRCT > 0.80 vs. FFRCT ≤ 0.80 (3.9% and 8.7%, P = 0.04), however, in patients with CAC scores ≥400 the risk difference between groups did not reach statistical significance, 4.2% vs. 9.7% (P = 0.24). A negative relationship between CAC scores and FFRCT irrespective of stenosis severity was demonstrated., Conclusion: FFRCT shows promise in identifying patients with stenosis and calcification who can be managed without further downstream testing. Moreover, an inverse relationship between CAC levels and FFRCT was demonstrated. Studies are needed to further assess the clinical utility of FFRCT in patients with extensive coronary calcification., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
17. Changes in blood pressure and systemic vascular resistance do not predict microvascular structure during treatment of mild essential hypertension.
- Author
-
Eftekhari A, Mathiassen ON, Buus NH, Gotzsche O, Mulvany MJ, and Christensen KL
- Subjects
- Adult, Aged, Blood Flow Velocity drug effects, Echocardiography, Female, Forearm blood supply, Humans, Hypertension pathology, Hypertension physiopathology, Hypertrophy, Left Ventricular diagnosis, Hypertrophy, Left Ventricular physiopathology, Male, Microvessels pathology, Microvessels physiopathology, Middle Aged, Plethysmography, Vascular Resistance physiology, Vasodilation drug effects, Antihypertensive Agents therapeutic use, Blood Pressure drug effects, Hypertension drug therapy, Microvessels drug effects, Vascular Resistance drug effects
- Abstract
Background: Essential hypertension is characterized by small artery remodeling and increased systemic vascular resistance (SVR). We hypothesized that changes in SVR index (SVRI) were associated with measures of small artery structure as reflected by minimum coronary and forearm vascular resistance (C-Rmin and F-Rmin, respectively). Also, we investigated how F-Rmin is related to C-Rmin, coronary flow reserve (CFR), left ventricular mass index (LVMI) and blood pressure (BP)., Method: Sixty-six never-treated patients with uncomplicated mild essential hypertension had the following measured at baseline: 24-h blood BP, LVMI, CFR and C-Rmin (echocardiography), F-Rmin (forearm plethysmography) and SVRI determined by a gas re-breathing method. After 6 months of antihypertensive therapy administered by the general practitioner, the patients returned for follow-up measurements., Results: Changes in SVRI did not correlate to changes in F-Rmin (r = 0.001, P = 0.98) or C-Rmin (r = 0.13, P = 0.39) but did correlate to changes in CFR (r = 0.30, P = 0.04). Further analysis was performed by assigning the patients into two groups according to the median of drop in F-Rmin. When adjusted in a multivariate model, changes in F-Rmin (-8.1 ± 3.2%) were significantly associated with changes in C-Rmin (-9.3 ± 4.9%) and LVMI (-6.9 ± 1.7%) (P < 0.01), but not to either 24-h BP, SVRI or CFR., Conclusion: The results show that changes in neither BP nor SVRI reflected changes in minimum vascular resistance. However, changes in the forearm and coronary microcirculation occurred in parallel. Moreover, we demonstrated that neither BP nor SVRI reduction can predict changes in microvascular structure in hypertension. Thus, direct measurements of microvascular structure are needed to determine whether improvement is obtained.
- Published
- 2012
- Full Text
- View/download PDF
18. Small artery structure is an independent predictor of cardiovascular events in essential hypertension.
- Author
-
Mathiassen ON, Buus NH, Sihm I, Thybo NK, Mørn B, Schroeder AP, Thygesen K, Aalkjaer C, Lederballe O, Mulvany MJ, and Christensen KL
- Subjects
- Adult, Buttocks pathology, Cardiovascular Diseases diagnosis, Female, Humans, Hypertension complications, Male, Middle Aged, Prognosis, Arteries pathology, Hypertension pathology, Tunica Media pathology
- Abstract
Objective: Structural abnormality of resistance arteries is a characteristic pathophysiological phenomenon in essential hypertension and can be assessed in vitro as an increase in the media: lumen ratio (M: L) of isolated small arteries. We have investigated whether M: L is a risk predictor in uncomplicated essential hypertensive patients. Recently, high M: L was demonstrated as a prognostic marker in patients at high cardiovascular risk, including normotensive type 2 diabetic patients. Since diabetes is associated with pressure-independent changes in M: L, the relevance of this finding to essential hypertension has been uncertain., Methods: We conducted a follow-up survey of 159 essential hypertensive patients, who had previously been submitted to a M: L evaluation while participating in a clinical trial. They composed a homogeneous moderate-risk group, with no concomitant diseases, and represented 1661 years of follow-up., Results: Thirty patients suffered a documented predefined cardiovascular event during follow-up. Increased relative risk (RR) was associated with M: L >or= 0.083 (mean level of the hypertensive cohort), RR = 2.34 [95% confidence interval (CI) 1.11-4.95], and with M: L >or= 0.098 (mean level of a normotensive control group + 2SD), RR = 2.49 (95% CI 1.21-5.11). Both results remained significant (RR = 2.19, 95% CI 1.04-4.64, and RR = 2.20, 95% CI 1.06-4.56, respectively) when adjusted for Heart Score level (10-year mortality risk-estimate, integrating age, gender, systolic blood pressure, cholesterol and smoking)., Conclusion: Abnormal resistance artery structure independently predicts cardiovascular events in essential hypertensive patients at moderate risk.
- Published
- 2007
- Full Text
- View/download PDF
19. Small artery structure adapts to vasodilatation rather than to blood pressure during antihypertensive treatment.
- Author
-
Mathiassen ON, Buus NH, Larsen ML, Mulvany MJ, and Christensen KL
- Subjects
- Acrylates pharmacology, Adult, Case-Control Studies, Echocardiography, Female, Humans, Imidazoles pharmacology, Male, Middle Aged, Thiophenes pharmacology, Ventricular Function, Left drug effects, Antihypertensive Agents pharmacology, Arteries drug effects, Blood Pressure drug effects, Vascular Resistance drug effects, Vasodilation drug effects
- Abstract
Objective: Correction of the abnormal structure of resistance arteries in essential hypertension may be an important treatment goal in addition to blood pressure (BP) reduction. We investigated how this may be achieved in a prospective clinical study., Methods: Plethysmography was used to measure forearm resting vascular resistance (Rrest) and minimum vascular resistance (Rmin) as a measure of vascular structure. Two different groups of patients with essential hypertension were examined at baseline and after 6 months of antihypertensive treatment. In group A, 21 patients with never-treated essential hypertension were treated by their general practitioners using a variety of drugs to allow an assessment of the drug-independent effects. In group B, 28 beta-blocker-treated patients were shifted to angiotensin II receptor blocker treatment (eprosartan) to allow vasodilatation with no change in BP., Results: In group A, mean ambulatory blood pressure (ABP) fell from 119 +/- 2 (SE) to 103 +/- 2 mmHg (P < 0.01), whereas mean ABP was unchanged in group B (100 +/- 1 to 99 +/- 1 mmHg, P = NS). Both groups showed similar reductions in Rrest (-33.4 and -28.5%, respectively) and in Rmin (-15.4 and -15.6%, respectively). There was a strong correlation between changes in Rrest and Rmin within both groups (r = 0.57, P < 0.01 and r = 0.68, P < 0.0001, respectively), whereas the change in BP in group A was not correlated to the change in Rmin (r = -0.03)., Conclusion: The correction of forearm resistance artery structure during antihypertensive treatment depends on the vasodilatation achieved rather than BP reduction.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.